Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5593759 | 1.00 | SLC6A3 (0.52) | SLC6A3 | |
| SCHEMBL3921318 | 1.00 | SLC6A3 (0.52) | SLC6A3 | |
| SCHEMBL1944024 | 1.00 | SLC6A3 (0.52) | SLC6A3 | |
| SCHEMBL7679057 | 1.00 | SLC6A3 (0.52) | SLC6A3 | |
| SCHEMBL13961124 | 1.00 | SLC6A3 (0.52) | SLC6A3 | |
| SCHEMBL12538468 | 1.00 | SLC6A3 (0.52) | SLC6A3 | |
| SCHEMBL1944023 | 1.00 | SLC6A3 (0.52) | SLC6A3 | |
| Hydrochloric Acid SCHEMBL10600725 | 0.98 | SLC6A3 (0.51) | SLC6A3 | |
| Hydrochloric Acid SCHEMBL10600718 | 0.98 | SLC6A3 (0.51) | SLC6A3 | |
| Hydrochloric Acid SCHEMBL10600732 | 0.98 | SLC6A3 (0.51) | SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264637-A1 | PREPARATION OF PAROXETINE HYDROCHLORIDE HEMIHYDRATE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2006-11-23 | — | — | US | claimed |
| WO-2007034270-A2 | IMPROVED PROCESS FOR THE PREPARATION OF (-) TRANS-N-METHYL PAROXETINE | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2007-03-29 | — | — | WO | disclosed |
| US-20060264637-A1 | PREPARATION OF PAROXETINE HYDROCHLORIDE HEMIHYDRATE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2006-11-23 | — | — | US | disclosed |
| EP-1366041-A4 | PREPARATION OF N-METHYLPAROXETINE AND RELATED INTERMEDIATE COMPOUNDS | TEVA PHARMA (IL) | 2004-12-22 | — | — | EP | disclosed |
| US-6777554-B2 | REACTING SESAMOL-TETRABUTYLAMMONIUM SALT WITH 4-(4-FLUOROPHENYL)-3-CHLOROMETHYL-N-METHYL-PIPERIDINE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-08-17 | — | — | US | disclosed |
| EP-1366041-A1 | PREPARATION OF N-METHYLPAROXETINE AND RELATED INTERMEDIATE COMPOUNDS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-12-03 | — | — | EP | disclosed |
| US-20020151567-A1 | Preparation of N-methylparoxetine and related intermediate compounds | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IR) | 2002-10-17 | — | — | US | disclosed |
| WO-2002062790-A1 | PREPARATION OF N-METHYLPAROXETINE AND RELATED INTERMEDIATE COMPOUNDS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-08-15 | — | — | WO | disclosed |
| US-20020010155-A1 | Novel process | SMITHKLINE BEECHAM P.L.C. | 2002-01-24 | — | — | US | disclosed |
| US-6066737-A | Process for the preparation of optically enriched 4-aryl-3-hydromethyl substituted piperidines to be used as intermediates in the synthesis of paroxetine | CHIROTECH TECHNOLOGY, LTD. (GB) | 2000-05-23 | — | — | US | disclosed |
| EP-0300617-B1 | Process for preparing aryl-piperidine carbinols | BEECHAM GROUP PLC (GB) | 1994-05-18 | — | — | EP | disclosed |
| US-5039803-A | Reduction, quaternization; selective production of cis isomer; antidepressants | BEECHAM PHARMACEUTICALS (GB) | 1991-08-13 | — | — | US | disclosed |
| EP-0152273-B1 | A PHENYLPIPERIDINE DERIVATIVE, AND ITS SALTS, THEIR PREPARATION, COMPOSITIONS CONTAINING THEM, AND THEIR THERAPEUTIC USE | A/S FERROSAN (DK) | 1989-09-06 | — | — | EP | disclosed |
| EP-0300617-A1 | Process for preparing aryl-piperidine carbinols | BEECHAM GROUP PLC (GB) | 1989-01-25 | — | — | EP | disclosed |
| US-4593036-A | (-)-Trans-4-(4-fluorophenyl)-3-[(4-methoxyphenoxy)methyl]-1-methylpiperidine useful as 5-HT potentiator | A/S FERROSAN (DK) | 1986-06-03 | — | — | US | disclosed |
| US-4585777-A | 5-HYDROXYTRYPTAMINE | A/S FERROSAN (DK) | 1986-04-29 | — | — | US | disclosed |
| EP-0152273-A2 | A phenylpiperidine derivative, and its salts, their preparation, compositions containing them, and their therapeutic use | A/S FERROSAN (DK) | 1985-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010155-A1 | Novel process | ADH1C, CBR1, ADH1A | SLC6A3 4582/4885 |
| US-20020151567-A1 | Preparation of N-methylparoxetine and related intermediate compounds | PNMT, INMT, SLC6A4 | SLC6A3 175/4885 |
| US-20060264637-A1 | PREPARATION OF PAROXETINE HYDROCHLORIDE HEMIHYDRATE | HTR5A, HTR6, HTR2B | SLC6A3 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.